Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase

Diabetes Care

Volumn 36, Issue 2, 2013, Pages 273-275

  Morrow, Linda ^a   Muchmore, Douglas B ^b   Hompesch, Marcus ^a   Ludington, Elizabeth A ^b   Vaughn, Daniel E ^b  

^a Profil Institute for Clinical Research   (United States)

^b Halozyme Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HYALURONIDASE; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; SHORT ACTING INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK REDUCTION;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN, SHORT-ACTING; MALE;

EID: 84873878280     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0808     Document Type: Article

References (15)

1. Holleman F, Hoekstra JB. Insulin lispro. N Engl J Med 1997;337:176-183
2. Lindholm A, Jacobsen LV. Clinical phar-macokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001; 40:641-659
3. Becker RH, Frick AD. Clinical pharma-cokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47:7-20
4. Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-183
5. Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005;165:1337-1344
6. Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther 1995;58:459-469
7. Rassam AG, Zeise TM, Burge MR, Schade DS. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. Diabetes Care 1999;22:133-136
8. Muchmore DB, Vaughn DE. Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. J Diabetes Sci Tech 2010;4:419-428
9. Frost GI. Recombinant human hyaluron-idase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4: 427-440
10. Vaughn DE, Yocum RC, Muchmore DB, et al. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyal-uronidase. Diabetes Technol Ther 2009; 11:345-352
11. Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M. Reduction in intrasubject variability in the pharmaco-kinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers. Diabetes Technol Ther 2011;13: 1039-1045
12. Heinemann L, Anderson JH Jr. Measurement of insulin absorption and insulin action. Diabetes Technol Ther 2004;6:698-718
13. US FDA Guidance for Industry. Bio-availability and bioequivalence studies for orally administered drug products-general considerations. Available at http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/ucm070124.pdf. Accessed 26 April 2012
14. Hompesch M, Muchmore DB, Morrow L, Vaughn DE. Accelerated insulin pharma-cokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care 2011;34:666-668
15. Hompesch M, Muchmore DB, Morrow L, Ludington EA, Vaughn DE. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluron-idase. Diabetes Technol Ther 2012;14: 218-224